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matching data over 2000-2010, 17,088 additional cases, 337 additional 
hospitalizations and 168 additional deaths could potentially be avoided annually 
with QIV versus TIV. There would be no additional benefits for well-matched 
years 2000-03 and 2009-10. In mismatched years benefits could range from 
minor, such as 2003-4 (100% mismatched, 0.4% influenza-B circulation) where 
578 additional cases, 11 additional hospitalizations and 6 additional deaths 
potentially avoided to significant impact, such as 2005-6 (98.8% mismatched, 70% 
influenza-B circulation) with 100,296 additional cases, 1,976 additional 
hospitalizations and 988 additional deaths potentially avoided. CONCLUSIONS: 
Our analysis predicts that using recent influenza-B circulation and vaccine 
matching data, in 6 out of 10 years, a strategy of vaccination with QIV would 
have been more effective than TIV in reducing the number of influenza cases, 
and associated hospitalisations and deaths. Retrospective analysis of influenza 
circulation suggests that co-circulation of influenza-B lineages persists and that 
mismatch is frequent and unpredictable. The use of QIV might aid in reducing 
the associated burden of mismatched influenza-B.  
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OBJECTIVES: Meningococcal disease (MD) is a serious public health problem 
worldwide. It mainly affects low-income countries with higher impact in the 
‘meningococcal belt’ located at the African Sub Sahara. Children younger than 5 
years old are the most affected age group, with the highest incidence in the first 
year of life. Our aim is to evaluate the cost-effectiveness of the introduction of 
routine vaccination with a tetravalent meningococcal conjugate vaccine (MCV-4) 
in the Colombian EPI. METHODS: An age-dependent Markov model, which 
followed a cohort of children under one year of age up to their life expectancy, 
was developed. Parameters of occurrence and care costs were based on data 
from National Surveillance System, official data sources, and literature review. 
Serotype coverage was taken from SIREVA NM Colombia surveillances from 2007 
to 2010. A 3 + 1 schedule and a vaccination price of US$ 30.00 per dose were 
assumed in the base case, compared against no vaccination (only treatment the 
disease). All cost are expressed in 2011 US dollars. RESULTS: Introduction of 
MCV-4 would avoid 34 cases of meningococcal meningitis (MM), 27 cases of 
meningococcal sepsis, and 10 deaths in the lifespan of each infant’s cohort 
evaluated. MCV-4 vaccination avoids 126 years of life (LY), or 165 disability 
adjusted life years (DALYs). Vaccination would costs raises to US$ 71 million. The 
ICER of vaccination strategy compared to no vaccination was estimated at US$ 
441,998, which is very higher than the Colombian GPD (US$ 6,883). 
CONCLUSIONS: Routine vaccination against Neisseria meningitides with MCV-4in 
Colombia would not be cost-effective with tetravalent conjugate vaccine in the 
base case analysis.  
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OBJECTIVES: Streptococcus pneumoniae causes significant morbidity and 
mortality worldwide in both children and adults. The aim of this analysis is to 
evaluate the cost-effectiveness of vaccinating colombian population over 50 
years with 13-valent pneumococcal conjugated vaccine (PCV 13) from the 
institutional perspective in Colombia. METHODS: A Markov model was adapted 
to Colombian settings, using a time horizon of 5 years (3% annual discount rate). 
Comparators were PCV13, PPSV23 and no vaccination, vaccine coverage was 70%. 
Population size over 50 years of a Colombian insurance institution (n: 775,301) 
adjusted according with Colombian data was included, transition probabilities 
were extracted from a literature review, medical costs were taken from a local 
study developed by the “Fundación Cardio Infantil”, vaccines costs were taken 
from local report (SISMED), the diseases incidence was retrieved from literature 
(Castañeda et al. 2010, Dickinson et al 2001), vaccines efficacies were taken from 
literature (for PCV13 children data from PCV7 studies were adjusted by 
immunosenescence) and costs are expressed in 2012 US$. Effectiveness 
measures were the number of pneumococcal diseases and deaths prevented, as 
well as life years (LY) gained saved. Probabilistic sensitivity analyses were 
performed. RESULTS: Over a 5-year period, vaccinating with PCV13 prevents 
1,427 cases of invasive pneumococcal disease compared to PPSV23 and 1847 
compared no vaccination; 1691 and 1470 cases of invasive pneumonia and 188 
and 256 deaths, respectively. PCV13 saves 101,564 LY’s compared to PPSV23 and 
92,261 LY’s compared to no vaccination. Total expected costs (vaccination + 
medical costs) were US$164.0M for PCV13, US$ 164.4 PPSV23 and US$155.0M for 
no vaccination. CONCLUSIONS: Vaccinating adults over 50 years with PCV13 in a 
Colombian insurance institution is a cost-saving alternative in comparison to 
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OBJECTIVES: Streptococcus pneumoniae causes significant morbidity and 
mortality worldwide in both children and adults. The aim of this analysis is to 
evaluate the cost-effectiveness of vaccinating the Bogota adult citizens (over 50 
years) with 13-valent pneumococcal conjugated vaccine (PCV 13) versus 23-
valent pneumococcal polysaccharide vaccine (PPSV23) and no vaccination from 
the public payer’s perspective in Colombia. METHODS: A Markov model was 
adapted to the Colombian public setting, using a time horizon of 4 years (3% 
annual discount rate). Comparators were PCV13, PPSV23 and no vaccination, 
vaccine coverage of 70% and projected Colombian population for 2013 were 
assumed, transition probabilities were extracted from literature review, medical 
costs were taken from a local study developed by the “Fundacion CardioInfantil”; 
vaccine prices were taken from the PAHO revolving fund price list, vaccines 
efficacies were taken from literature (for PCV13 children data from PCV7 studies 
were adjusted by immunosenescence), diseases incidences were retrieved from 
literature (Castañeda et al. 2010, Dickinson et al 2001) and costs were expressed 
in 2012 US$. Effectiveness measures were the number of pneumococcal diseases 
and deaths prevented, as well as life years (LY) saved. RESULTS: Over a 4-year 
period, vaccinating with PCV13 and PPSV23 against no vaccination prevents 2587 
and 1804 cases of invasive pneumococcal disease; 2365 and 11 cases of invasive 
pneumonia and 357 and 139 deaths respectively. PCV13 saves 518 LY’s compared 
to PPSV23 and 44.9 LY’s compared to no vaccination. Total expected saving 
(vaccination + medical costs) for PCV13 was US$5.8M against PPSV23 and US$3.2 
against no vaccination (total expected costs: US$54.5M; US$60.3M and US$57.7M 
respectively). CONCLUSIONS: Vaccinating adults over 50 years with PCV13 in 
Bogota is a cost-saving alternative in comparison to PPSV23 and no vaccination 
(US$3.5 and US$1.9 savings per patient, respectively). Study findings could 
support the decision-making process in favor of PCV13.  
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OBJECTIVES: To evaluate the cost-effectiveness results of introducing PCV7 into 
City Immunization Programs in 7 urban China. METHODS: Six health status 
contained pneumococcal meningitis (inpatient), pneumococcal septicemia 
(inpatient), pneumonia (all-cause, inpatient), pneumonia (all-cause, outpatient), 
mild otitis media (all-cause, outpatient) and sever otitis media (all-cause, 
outpatient )were considered. Age-specific cost was collected from electronic 
patient records (2010) from 14 hospitals in 7 cities in China. Two hospitals in 
each city was selected (1 Children’s Hospital, 1 Comprehensive Hospitals) and 7 
field cities including Beijing, Guangzhou, Shenzhen, Wuhan, Xi’an, Chengdu and 
Shenyang were enrolled. Direct medical cost included registry fee, medications, 
diagnostic tests fee, and hospitalization expenditure. A discount rate of 5% was 
applied. One-way sensitivity analyses were performed to evaluate the sensitivity 
of the results to data inputs. RESULTS:   As Category II vaccinePCV7 was not cost 
effective due to the private market unit price and low penetration rate. However, 
vaccination of children under 2 years old from 7 urban China in a CIP is 
estimated to prevent 366,337 cases from infection and 3,415 cases from death 
compared to no vaccination. From a payer perspective, a PCV7 CIP had an ICER of 
RMB17, 977/QALY in Beijing, RMB79,180/ QALY in Chengdu, RMB72,406/QALY in 
Guangzhou, RMB70,896/QALY in Shenyang,RMB69,792/QALY in Shenzhen, 
RMB64,152/QALY in Wuhan and RMB76,864/ QALY in Xian. CONCLUSIONS: The 
empirical results show that under the current situation with a 860 Yuan/ dose 
vaccination price and a 85% vaccination rate, when take PCV7 into the city 
immunization plan, the spending of the cost is worth in Beijing, Guangzhou and 
Shenzhen and is acceptable in Wuhan, Shenyang, Chengdu and Xi’an.  
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OBJECTIVES: Trivalent influenza vaccines contain two influenza A and one 
influenza B strains. The Food and Drug Administration has approved live 
attenuated and inactivated quadrivalent vaccines (containing two influenza A 
and both influenza B strains). Our aim was to compare the cost-effectiveness of 
vaccination with quadrivalent versus trivalent seasonal influenza vaccines. 
METHODS: A dynamic transmission model was used to estimate the age 
stratified temporal trend in influenza virus infection incidence. The population 
was divided into 5 subgroups: Susceptible, Exposed, Infectious, Recovered, and 
Vaccinated. We estimated health service resource utilisation from published 
disease-specific probabilities of consulting a primary care physician, 
hospitalization, and death. Disease burden was expressed in clinical (health 
service utilization and death), quality of life, and economic terms. Both a payer 
and societal perspectives were adopted. We compared the costs and outcomes of 
quadrivalent vaccination with those of trivalent vaccination, assuming price 
parity between vaccines. All costs and benefits were discounted at a rate of 3% 
per annum. Probabilistic sensitivity analyses were conducted. RESULTS: Adding 
a second influenza B strain to the trivalent seasonal influenza vaccines at the 
same vaccine prices was estimated to be cost-saving in the US. Estimated mean 
annual cost savings totalled $3.9 billion (societal perspective) and $1.6 billion 
(third-party payer perspective). On average, annual clinical benefits included 
over 13.5 million averted infections, over 510,000 averted primary care 
consultations, approximately 80,000 averted hospitalizations and 5,000 deaths 
prevented. The quadrivalent vaccines dominated their trivalent equivalents, 
saving cost and generating QALY’s. All sensitivity analyses were cost-saving. 
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CONCLUSIONS: Quadrivalent seasonal influenza vaccines, at price parity with 
trivalent vaccines, appear to be highly cost-saving from the third-party payer 
and the societal perspectives.  
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OBJECTIVES: Clinical evidence shows that adherence levels ≥90% are required to 
maximize HAART effectiveness on HIV patients. In Mexico, universal access to 
HAART exists; however, average adherence level is 79.8% (95% CI: 77.8-81.8). The 
purpose of this study was to analyze two patient-level reminder interventions 
aimed to increase adherence levels. METHODS: The study design was a cost-
effectiveness analysis from the governmental perspective. All the costs were 
expressed in 2010 constant USD. A natural history of disease dynamic model for 
HIV was used to estimate the following parameters: CD4 and CD8 cell replication 
and mortality rates, as well as infectivity rates of individuals simulated. Also, we 
analyzed data from a national representative survey of HIV patients on HAART 
(N=2289) and presenting at 50 governmental hospital/clinics to obtain adherence 
levels. With these parameters we used a Markov model to estimate life 
expectancy, total patients’ care costs, and therefore cost-effectiveness ratios. 
Patients were classified as adherent (≥90%) and non-adherent (<90%). We 
evaluated two patient-level reminder interventions: (1) three reminder text 
messages (SMS) sent daily to the patient’s cell phone, and (2) a pill reminder. 
Both were modeled throughout the patients’ lives. We performed sensitivity 
analysis for both adherence levels and costs. RESULTS: Of the 2289 patients, 26% 
were adherent (≥90%) (mean adherence level: 79.8%). We did not find statistically 
significant differences between adherents and non-adherents in 
sociodemographic characteristics. Seventy percent reported that HAART daily 
intake omission is the main reason for non-adherence. Interventions increase 
life expectancy by 2.6 years (SMS) and 3.1 years (pill reminder) with an 
incremental cost of $4050 and $5552, respectively. Incremental cost-effectiveness 
ratios are $207 and $637 per year life gained (3% annual discount rate). 
CONCLUSIONS: Both interventions are below one GDP per capita; therefore, they 
are cost-effective and could be considered for implementation in our country.  
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OBJECTIVES: To determine the incremental cost-effectiveness of linezolid versus 
vancomycin using data from a clinical trial assessing treatment of nosocomial 
pneumonia due to MRSA in hospitalized adults. METHODS: A cost-effectiveness 
analysis from the U.S. hospital-payer perspective was piggybacked onto a phase 
4, randomized, double-blind, multicenter trial (Wunderink et al, Clin Infect Dis 
2012) in nosocomial pneumonia patients with culture-proven MRSA 
[microbiologic confirmed intent-to-treat (mITT) cohort]. Efficacy was measured 
by treatment success (defined as Cure+Improvement) at the end of study (i.e., 7-
30 days after the end of treatment). Direct medical costs (USD, 2011 values) were 
calculated from the health care resources used, including study medication, 
hospitalization, mechanical ventilation, and dialysis. Nonparametric 
bootstrapping was conducted to calculate confidence intervals (CI) for costs, 
efficacy, and incremental cost-effectiveness ratios (ICER). One-way sensitivity 
analyses were conducted to evaluate the uncertainty and cost drivers. RESULTS: 
Data from 391 patients (186 linezolid, 205 vancomycin) were analyzed. A greater 
proportion of linezolid patients achieved treatment success versus vancomycin 
patients [mean (95% CI)]: 55% (48.3%-61.9%) versus 45% (38%-52.3%). Total costs 
per linezolid patient were $48,929 ($45,375-$52,483) compared to $46,665 
($43,201-$50,128) per vancomycin patient. The point estimate for the ICER of 
linezolid versus vancomycin was $16,516. The median ICER from bootstrapping 
was $16,219 (95% percentile: $100,487). Of the 10,000 bootstrap simulations, 73% 
had greater efficacies and higher costs (positive ICERs) for linezolid, 24% had 
greater efficacies and lower costs for linezolid (linezolid dominated vancomycin), 
and <2% had greater efficacies and lower costs for vancomycin (vancomycin 
dominated linezolid). Key cost drivers included number of ICU and general ward 
days in each treatment group. Addition of empirical treatment had a relatively 
small impact on ICER. CONCLUSIONS: In this clinical trial population, linezolid 
appears to be cost-effective compared to vancomycin in treating patients with 
nosocomial pneumonia due to MRSA.  
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OBJECTIVES: Posaconazole has shown superior clinical efficacy than 
Fluconazole/Itraconazole (FLU/ITRA) in the prevention of invasive fungal 
infections (IFIs) among patients with neutropenia resulting from chemotherapy 
for acute myelogenous leukemia (AML) or the myelodysplastic syndrome (MDS). 
Previous study has shown that Posaconazole is cost-effective versus FLU/ITRA in 
the 2007 U.S. health care setting.To reflect the changes in health care cost and 
the changes in drug prices, the study aims to provide an update on the cost-
effectiveness of Posaconazole in the current U.S. health care setting. METHODS: 
A previously published (O’Sullivan et.al., VIH 2009) cost effectiveness model was 
used to assess the cost-effectiveness of posaconazole versus FLU/ITRA in the 
prevention of IFIs among patients with neutropenia resulting from 
chemotherapy for AML or MDS. Drug efficacy, mortality related to IFIs and death 
from other causes, were all estimated using data from a randomized clinical trial 
(Cornely et.al., NEJM 2007). IFI treatment costs were inflation-adjusted over last 6 
years (2007-2012) and drug costs were based on 2012 IMS data. RESULTS: Trial 
data estimates the probability of an IFI over 100 days of follow-up while on 
Posaconazole to be lower than FLU /ITRA (0.05 vs. 0.11).The duration of treatment 
on Posaconazole is 25 days compared to 29 days with FLU or ITRA. Total costs of 
prophylaxis with FLU /ITRA and posaconazole is $5,293 and $5,859 respectively. 
The incremental cost-effectiveness ratios (ICER) for Posaconazole versus 
FLU/ITRA are estimated to be $8,805 per IFI avoided and $8,439 per life-year 
saved. CONCLUSIONS: Posaconazole is cost-effective to FLU or ITRA in the 
prevention of IFIs among neutropenic patients with AML and MDS in the current 
U.S. health care setting.  
 
PIN66  
POTENTIAL EPIDEMIOLOGICAL AND ECONOMIC IMPACT OF DIFFERENT 
ROTAVIRUS VACCINES IN LOW AND MIDDLE INCOME COUNTRIES  
Paternina-Caicedo A1, De la Hoz-Restrepo F2, Carrasquilla-Sotomayor M1,  
Alvis-Zakzuk N1, Alvis-Guzmán N1 
1Universidad de Cartagena, Cartagena de Indias, Colombia, 2Universidad Nacional de Colombia, 
Bogota, Colombia  
OBJECTIVES: Several studies have shown rotavirus vaccine is cost effective in 
low and middle income countries. Despite this, competing choices of rotavirus 
vaccines make the selection of either vaccine difficult for health decision-makers 
in low resource settings. The objective of this study is to assess cost 
effectiveness of the monovalent (MNV) and pentavalent (PTV) rotavirus vaccines 
on children mortality in 116 low and middle income countries that represent 
~99% of rotavirus mortality. METHODS: A decision economic model was built to 
estimate the effect of MNV or PTV vaccination. Inputs were gathered from 
international databases, previous research and a systematic review of MNV and 
PTV vaccine effectiveness. Outcomes were reported in terms of cost per 
disability-adjusted life-year (DALY) averted, comparing no vaccination being 
implemented on selected countries for the year 2010 with either MNV or PTV 
introduction. Costs were expressed in 2010 international dollars. RESULTS: Low 
and middle income countries would have had 601,511 deaths in 2010, if rotavirus 
vaccine would not have been used. Under no vaccine scenario, 139 DALYs per 
1000 children, 1.57 million inpatient and 9.17 million outpatient cases would 
occur every year. MNV would avert 53.3% of rotavirus-related deaths, and PTV 
57.9%. MNV and PTV were highly cost effective worldwide, according to WHO 
criteria (less than per capita gross domestic product). I$143 cost per DALY for 
MNV versus I$152 cost per DALY for PTV. Uncertainty was lower in low income 
countries. CONCLUSIONS: Rotavirus vaccine is cost-effective in all analyzed 
countries. Despite cost effectiveness analysis is a useful tool for decision making 
in middle income countries, for low income countries health-decision makers 
should also assess the impact of introducing either vaccine on local resources, 
and budget impact analysis of vaccination.  
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OBJECTIVES: Aspergillosis is the second cause of invasive fungal infections with 
high mortality rates. The objective of this research is to evaluate the cost-
effectiveness of amphotericin B(AB) 1.5mg/kg/day, amphotericin B liposomal(AL) 
3mg/kg/day, caspofungin(CA) 50mg/day, voriconazol 8mg/kg/day(VO) including 
maintenance oral Voriconazol 400mg/day scheme in the treatment of 
aspergillosis under the Brazilian private health care system perspective. 
METHODS: A decision tree model was built considering sequential treatments, 
from which patients could respond to one initial treatment and continue to a 
maintenance phase of the same medication, or do not respond due to either 
inefficacy or adverse events and switch treatments with assumed equal chance 
to use one of the other options. Effectiveness measures were mortality, clinical 
response and days of hospitalization, calculated by indirect comparison of a 
literature systematic review. Only direct costs were considered, and were 
obtained from CFM/CBHPM2010 for medical procedures, MOH/CMED 
December2012 price list for medications, and BRASINDICE for materials. Values 
were represented in 2012USD. A time horizon no longer than 4 weeks was 
considered, thus discounting was not applied. One-way sensitivity analysis 
considered de-hospitalization in maintenance phases while using oral 
voriconazol. RESULTS: Clinical response rates were 36.40%(AB), 34.60%(AL), 
34.20%(CA), 56.67%(VO), mortality rates were 50.90%(AB), 48.70%(AL), 44.70%(CA), 
34.10%(VO) and hospitalization days were 26.35(AB), 24.68(AL), 25.33(CA), 
22.55(VO). Expected treatment costs were US$33,838.33(AB), US$71,186.24(AL), 
US$46,223.28(CA) and US$36,255.09(VO). Considering AB as the baseline for cost-
effectiveness, VO presented an incremental cost-effectiveness ratio(ICER) of 
26,723.07 while other options were dominated with higher costs and lower 
effectiveness. If de-hospitalization was considered, VO would sum 14.62 
hospitalization days, treatment cost of US$32,755.71 and an ICER of US$9,459.23. 
CONCLUSIONS: Assuming a willingness to pay of US$32,621.93 (3 times the 
